Filip Borgions

Chief Technology Innovation Officer at argenx

Filip Borgions is Vice President, Global Head of Technical Operations at argenx and joined the company in 2015. In this role, Filip leads global CMC development, clinical and commercial manufacturing, supply chain and logistics. He has played a pivotal role in the path to approval and launch of the Company’s first commercial product VYVGART and the development of the robust pipeline of product candidates.

Previously, Filip worked in roles of increasing responsibility within CMC at Thrombogenics where he played a crucial role in the global development and commercial launch of Jetrea. He started his industry career at Schering-Plough, currently MSD, in the global CMC and regulatory team. He holds a Ph.D. in Medicinal Chemistry from the Rega Institute at University of Leuven and a Pharmacy degree and a Postgraduate in Business Economics also from University of Leuven.

Location

Ghent, Belgium

Links


Org chart


Teams


Offices

This person is not in any offices


argenx

31 followers

Argenx discovers, designs and develops innovative antibody therapeutics for its own pipeline of treatments for cancer and autoimmune diseases and for its partners. Harnessing our technology and know-how, we aim to meet the needs of patients by engineer...


Industries

Headquarters

Gent, Belgium

Employees

501-1,000

Links